| ˷5 յ 5 Ʈ ˱ Ұϴ ڳԴϴ.
1. Ư 22 ڽ 鿪 ſ 22 ڽ 忡 յΰ ִ. ڽڽ Ưʸ Ҵ. 俹 𰡴 11000~15000 ϴ 11000 Ȯƴ.
5~6 俹 472 ߰ 206 1 ߴ. 12~13 Ϲ û ڽڿ ̴. ֽļ 395̰ ǥ ְ Z̴.
Ǵ ݾ 430̴. ſҴ 2024 ӻ ڱ(284) ڱ(146) ȹ̴. ӻܰ迡 ⸸ B ġ(ӻ 2b ) B (CVI-HBV-001: ӻ 1/2a Ϸ, CVI-HBV-002: ӻ 1 ) (ӻ 1 INDû) ӻ ڱ ̴.
ſ 忹ֽļ 26429162 39.4% شϴ 10402570ְ 밡 ̴. Ȯ 3(ִ ̿ Ư , ǥ̻) 40%(1064) 3Ⱓ ȣȴ.
2. ſ, 鿪 ÷ š鿪ġ
ſҴ ü 鿪 ÷ پ ȯ ̾ , ġ 鿪ġ /ϴ ̿ ó̴. 鿪 ü 鿪 ÷ ȯ ִ First-in-Class Ǵ Best-in-Class ž ϰ ִ. ġо߷ ȮϿ 鿪 Ÿ̵ ġŰ 鿪ġ ϰ ִ.
2000 ϻп Ͽ ȫ ڻ翡 ֽȸ κ ƴ. 2011 ִ ֽȸ ̿κ ڸ ġ ÿ ִ Ͽ ̿ Եƴ. 2014 ſ ǥ̻簡 ӵư 濵 ̲ ִ.
ȸ ܺ Ʈ(CMO) ȰϿ ӻ Ǿǰ ŹѴ. , ӻǾǰ Ź GMP CMO ѱſ Ƿϰ ſ ü , ȮǾ ִ.
2000 2003 6 ó Ư㸦 ߰ Ư 37, Ư 14 51 Ư㸦 ϰ ִ. ش Ư 鿪(Adjuvant), MBL(Mannose-Binding Lectine), ǥ+ھ HBV չ, HBV 뷮 , HBV pre-S ܹ 12 з ǰ ִ.
(ڷ : ſ IR BOOK)
3. 鿪 ÷ Ȱ Ʈ Ȯ强
ſҰ ü 鿪 L-Pampo Lipo-Pam 鿪 ȯڿ T ȰȭŰ, ü 鿪 ֵ ȵ TLR2 TLR3 ̷ ո鿪 ̴. ſҴ ̷ ȰϿ B ġ(CVI-HBV-002), ̾ B (CVI-HBV-001, CVI-HBV-002), (CVI-VZV-001) ߰ ӻ ̴.
ſ B ġ CVI-HBV-002 ӻ 2b ߴ. 2021 Zﺴ, б 9 ӻ ڸ 2022 ʱ ׳(Tenofovir) 迭 ̷ ϷϿ 2023 ݱ ӻ Ϸ ȹ̴. ̾ B ӻ 1 IND ӻ غ ̸, 2021 ġ ӻ 1 IND ӻ ȹϰ ִ.
ƿ ü 鿪 Ȯ强 شȭ ִ Ÿ̵ Ϲ, ο Ȯ ȹ̴. ̸ Ͽ Pre-IPO ġ ͺƮ ϷPE 230 ȯä(CB) ִ. ߰ ȭ ӻ ڱ ϱ ġ IPO Ͽ ڱ ȹ̴.
ſ ڴ "ȿ ʿ ˷ , Ϻ, ο ſ 鿪 L-pampo Ͽ ȿ ȿ Ȯ ִ"鼭 " ο L-pampo Ͽ B, COVID-19, ι̷, Ϲ Ȯ ɼ ȮϿ, Lipo-pam 鿪 ȿӸ ƴ϶ DNA Ȥ RNA ü Ȱ Ȯߴ" ߴ.
(ڷ : ſ IR BOOK)
4, 2023
Ϲ ſҿ ߿ ϴ ̿ ó ֿ ü âϴ . Ʈʿ ϰ Ǹ ǿ ü , ܰ Ͻ Ǿǰ οƼ ϰ ȴ.
ſҴ ֱ 3Ⱓ þ Ǹ 뿪 ؿԴ. Ⱓ Ͼǰ ̿а ü 뿪 뿪 ߰ ̱ ġ Ark Diagnostics, Inc. þ Ϻ ݿƴ. ٸ ڸ ְ ӻ DZ ս ° ̾ ȴ.
ݱ 5̴. 2 ֽ̾(Aston Science) 2031 Ը ü߰ 4 ̴. Ͻ οƼ ݾ ǿ ش Ⱓ νĵ ̴. ڼ ֽ̾ AST-021p ܵ ӻ 1 ̴.
ȸ " ӻ ô B ġ ӻ 2b Ǵ 2022 ȴ"鼭 " ߰ ӻ ű ϰ Ѵ" ߴ. ̿ 2021 2022 6 ϴ 2023 321, 2024 1081 ϰ 2023 ڷ ȯ ̴.
(ڷ : ſ IR BOOK)
5. 鿪 о ۷ 濵
ſ ǥ̻ â ȫ ڻ Բ â ú ȸ 濵Ȱ ؿԴ. â ϻпҿ Ű ̷ ϰ ִ. 2011 ſ ְִ ̿ 2014 ǥ̻ ϸ ű 鿪 ߰ ̸ Ȱ ߿ ϰ ִ.
IR ڷῡ ǥ̻縦 CFO, Ⱥö R&D , R&D μ, R&D ȹ , ϼ ӻȹ ֿ 濵 Ұߴ. CFO ڿ SK 쿡 ̿ Ż ߰ ſ 濵 ϰ ִ.
å Ⱥö () ſ â շϿ 20 ̻ ٹ ̸, μ ð ִ շ Harvard ߺǴ 10Ⱓ ϸ õ 鿪 ߾.
ľϰ ⼺ ϴ ϴ R&D ȹ () Ͽ ΰ Ѵ. ϼ ̿ տ Ҽ ſ ӻȹ ϰ ִ.
( 0)